These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8439644)

  • 1. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome?
    de Jong PE; Anderson S; de Zeeuw D
    J Am Soc Nephrol; 1993 Jan; 3(7):1333-41. PubMed ID: 8439644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors in chronic renal failure.
    Opsahl JA; Abraham PA; Keane WF
    Drugs; 1990; 39 Suppl 2():23-32. PubMed ID: 2188823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake.
    Rodrigo R; Bravo I; Pino M
    Nutr Rev; 1996 Nov; 54(11 Pt 1):337-47. PubMed ID: 9110562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load.
    Garini G; Mazzi A; Buzio C; Mutti A; Allegri L; Savazzi G; Borghetti A
    Nephrol Dial Transplant; 1996 Apr; 11(4):628-34. PubMed ID: 8671850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ACE inhibitor effects on structure and function of the glomerular basement membrane].
    Hasslacher C; Bostedt-Kiesel A; Kempe HP
    Klin Wochenschr; 1992; 69 Suppl 29():39-44. PubMed ID: 1614191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective therapy in patients with nondiabetic nephropathies.
    Pisoni R; Ruggenenti P; Remuzzi G
    Drugs; 2001; 61(6):733-45. PubMed ID: 11398906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action.
    Heeg JE; de Jong PE; de Zeeuw D
    Clin Sci (Lond); 1991 Sep; 81(3):367-72. PubMed ID: 1655338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.
    de Jong PE; Heeg JE; Apperloo AJ; de Zeeuw D
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S28-32. PubMed ID: 1382162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
    Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G
    J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The antiproteinuric action of angiotensin-converting enzyme inhibitors in chronic glomerulonephritis and diabetic nephropathy].
    Kutyrina IM; Tareeva IE; Shestakova MV; Gerasimenko OI; Zverev KV; Rogov VA; Sheremet'eva OV
    Ter Arkh; 1994; 66(6):19-22. PubMed ID: 7940357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril.
    Heeg JE; de Jong PE; Vriesendorp R; de Zeeuw D
    Am J Nephrol; 1990; 10 Suppl 1():94-7. PubMed ID: 2175149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
    Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
    Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on proteinuria.
    Glassock RJ
    Am J Nephrol; 1990; 10 Suppl 1():88-93. PubMed ID: 2256481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of proteinuria by angiotensin converting enzyme inhibition.
    Heeg JE; de Jong PE; van der Hem GK; de Zeeuw D
    Kidney Int; 1987 Jul; 32(1):78-83. PubMed ID: 3041097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.
    Ruggenenti P; Mosconi L; Sangalli F; Casiraghi F; Gambara V; Remuzzi G; Remuzzi A
    Kidney Int; 1999 Mar; 55(3):984-94. PubMed ID: 10027935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic measures in proteinuric nephropathy.
    Praga M
    Kidney Int Suppl; 2005 Dec; (99):S137-41. PubMed ID: 16336567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.